Articles www.thelancet.com Published online November 11, 2025 https://doi.org/10.1016/S0140-6736(25)02114-21 Published Online November 11, 2025 https://doi.org/10.1016/ S0140-6736(25)02114-2 Houston Methodist Hospital, Houston, TX, USA (Prof M…
Articles
www.thelancet.com Published online November 11, 2025 https://doi.org/10.1016/S0140-6736(25)02114-21
Published Online
November 11, 2025
https://doi.org/10.1016/
S0140-6736(25)02114-2
Houston Methodist Hospital,
Houston, TX, USA
(Prof M Noureddin MD);
Houston Research Institute,
Houston, TX, USA
(Prof M Noureddin); Pinnacle
Clinical Research, San Antonio,
TX, USA (S A Harrison* MD);
MASLD Research Center,
Division of Gastroenterology
and Hepatology, University of
California at San Diego, La Jolla,
California, USA
(Prof R Loomba MD); Summit
Clinical Research, San Antonio,
TX, USA (N Alkhouri MD);
Clinical Research Institute of
Ohio, Westlake, OH, USA
(N Alkhouri); Indiana University
School of Medicine,
Indianapolis, IN, USA
(Prof N Chalasani MD); Fresno
Clinical Research Center,
Fresno, CA, USA
(M Y Sheikh MD); Altimmune,
Gaithersburg, MD, USA
(S Tomah MD, J A Gutierrez MD,
S Urbina MD, J J Suschak PhD,
R Brown MSc, O Odili PharmD,
J Yang PhD, S Keeton PhD,
M S Roberts PhD,
S K Browne MD,
M S Harris MD MS); Scripps
Clinic, La Jolla, CA, USA
(J A Gutierrez); Covenant
Metabolic Specialists, Fort
Myers, FL, USA (G Neff MD);
California Liver Research
Institute, Pasadena, CA, USA
(E Mena MD)
*Deceased
Correspondence to:
Prof Mazen Noureddin, Houston
Methodist Hospital, Houston,
TX 77030, USA
mnoureddin@
houstonmethodist.org
Safety and efficacy of weekly pemvidutide versus placebo for
metabolic dysfunction-associated steatohepatitis (IMPACT):
24-week results from a multicentre, randomised, double-
blind, phase 2b study
Mazen Noureddin, Stephen A Harrison, Rohit Loomba, Naim Alkhouri, Naga Chalasani, Muhammad Y Sheikh, Shaheen Tomah, Julio A Gutierrez,
Silvia Urbina, John J Suschak, Randy Brown, Ozioma Odili, Jay Yang, Stephine Keeton, Guy Neff, Edward Mena, M Scot Roberts, Sarah K Browne,
M Scott Harris
Summary
Background GLP-1–glucagon dual receptor agonists such as pemvidutide have shown promise in treating metabolic
dysfunction-associated steatohepatitis (MASH). The aim of this trial was to assess the effects of pemvidutide on
MASH resolution and fibrosis improvement in patients with liver fibrosis stage F2 or F3 MASH at 24 weeks of
treatment.
Methods IMPACT is an ongoing 48-week international, randomised, double-blind, placebo-controlled, phase 2b trial
in patients with biopsy-confirmed MASH and fibrosis stage F2 or F3. Patients from 83 sites in the USA and Australia
were randomly assigned 1:2:2 to receive once-weekly subcutaneous pemvidutide (1·2 mg or 1·8 mg), administered
without dose titration, or placebo. The dual primary endpoints were MASH resolution without worsening of fibrosis
or at least one stage liver fibrosis improvement without worsening of MASH at 24 weeks in the intention-to-treat
population. This trial was registered with ClinicalTrials.gov, NCT05989711.
Findings From July 27, 2023, to April 29, 2025, 1557 patients were screened and 212 patients were randomly assigned.
MASH resolution without fibrosis worsening was observed in 18 (20%) of 86 patients in the placebo group,
24 (58%) of 41 patients in the 1·2 mg pemvidutide group (difference of 38% [95% CI 21–56]; p<0·0001), and 45 (52%)
of 85 patients in the 1·8 mg pemvidutide group (difference of 32% [95% CI 19–46]; p<0·0001). Fibrosis improvement
without worsening of MASH was observed in 24 (28%) of 86 patients in the placebo group, 13 (33%) of 41 patients in
the 1·2 mg pemvidutide group (difference of 5% [95% CI −13 to 22]; p=0·59), and 30 (36%) of 85 patients in the
1·8 mg pemvidutide group (difference of 8% [95% CI −6 to 22]; p=0·27). Adverse events were reported in 32 (78%) of
41 patients receiving 1·2 mg pemvidutide, 69 (81%) of 85 patients receiving 1·8 mg pemvidutide, and 58 (67%) of
86 patients receiving placebo, the majority of which were mild or moderate in severity. Pemvidutide was well tolerated,
with discontinuations due to adverse events in none of 41 patients in the 1·2 mg pemvidutide group, one (1%) of
85 patients in the 1·8 mg pemvidutide group, and two (2%) of 86 patients in the placebo group.
Interpretation Pemvidutide treatment met the primary endpoint of MASH resolution without worsening of fibrosis at
24 weeks but did not meet the other primary endpoint of fibrosis improvement without worsening of MASH at this
timepoint. Additional trials of longer duration are planned.
Funding Altimmune.
Copyright © 2025 Elsevier Ltd. All rights reserved, including those for text and data mining, AI training, and similar
technologies.
Introduction
Metabolic dysfunction-associated steatotic liver disease
(MASLD) is a growing public health threat, affecting up
to 38% of the population globally.
1,2
In the liver, metabolic
syndrome can lead to MASLD in up to 80% of patients
with obesity.
3
Steatosis can lead to inflammation
(steatohepatitis) and hepatocyte ballooning with or
without fibrosis, with up to 20–30% of patients with
MASLD progressing to metabolic dysfunction-associated
steatohepatitis (MASH).
4,5
MASH is associated with high
morbidity, including a higher prevalence of poor
cardiovascular, oncological, and hepatic outcomes and
associated mortality.
6
Notably, many of the primary
drivers of mortality in non-cirrhotic MASH patients are
obesity-related.
2
Resmetirom, the first US Food and Drug
Administration-approved therapy for MASH, was
approved in 2024 based on improvements in MASH
resolution without worsening of fibrosis, and fibrosis
improvement without worsening of MASH, but
treatment was not associated with weight loss greater
than that achieved with lifestyle counselling on nutrition
Articles
www.thelancet.com Published online November 11, 2025 https://doi.org/10.1016/S0140-6736(25)02114-22
and exercise.
7
Semaglutide, a GLP-1 receptor agonist, was
approved for the treatment of MASH on the basis of
positive results on MASH resolution and fibrosis
improvement, and although patients had significant
weight loss, 72 weeks of treatment was required.
8
Although both approved monotherapies were found
effective in the treatment of MASH, it is possible that a
combined therapeutic approach could provide both rapid
effects on MASH and reductions in bodyweight.
Dual GLP-1–glucagon receptor agonists are unimolecular
peptide molecules that combine activity on both the GLP-1
and glucagon receptors, addressing the pathophysiology of
MASH directly via glucagon effects in the liver and
through reductions in bodyweight and anti-inflammatory
effects mediated by GLP-1.
9
A phase 2 trial of the GLP-1–
glucagon dual agonist survodutide has shown promising
effects in improving liver histology in MASH patients at
48 weeks of treatment. However, patient discontinuations
due to drug-related adverse events were observed despite
the inclusion of a lengthy dose titration scheme.
10
Pemvidutide is a 29-amino acid GLP-1–glucagon dual
receptor agonist peptide developed for the treatment of
MASH. In contrast to the GLP-1-biased activity of
survodutide and other GLP-1–glucagon dual agonists,
pemvidutide has 1:1 agonist potency at both receptors.
11
Further, on an equimolar basis, pemvidutide displays
slower kinetics of entry into the bloodstream and reduced
peak plasma concentrations while maintaining overall
exposure that is similar to most GLP-1 based agents,
possibly due to the EuPort glycolipid surfactant
conjugation used to increase the plasma half-life of the
peptide.
11
These pharmacokinetic properties might
eliminate the need for dose titration, since gastrointestinal
side-effects with GLP-1-based agents are related to peak
concentration.
12
A previous phase 1 study showed
promising effects on liver fat and bodyweight in MASLD
after up to 24 weeks of use.
13
Here, we report the primary efficacy outcomes after
24 weeks of treatment in the IMPACT phase 2b study of
pemvidutide in patients with biopsy-proven MASH
(NCT05989711).
Methods
Study design
The IMPACT trial is a randomised, double-blind,
placebo-controlled, dose-finding, phase 2b trial done at
83 sites in the USA and Australia. A prespecified analysis
of the primary histological endpoints was done when all
patients reached week 24, with on-treatment follow-up to
48 weeks for assessment of safety and non-invasive
biomarker response. The protocol (appendix p 20) was
conducted in accordance with Declaration of Helsinki,
International Council for Harmonisation guidelines and
Good Clinical Practice principles, and applicable
regulations. All enrolled patients provided written
informed consent. The sponsor (Altimmune) designed
the trial, without patient or public involvement, and was
responsible for data collection and analysis. Institutional
review board approval was provided by WCG IRB
(approval number 20231239) in the USA and St Vincent’s
Hospital Melbourne HREC (approval number 287/23) in
Australia.
Participants
Eligible patients were aged 18–75 years with biopsy-
confirmed MASH with a non-alcoholic fatty liver disease
activity score (NAS)
14
of at least 4 (scale of 0–8, with
higher scores reflecting more severe disease) with at least
1 point in each subcomponent. The subcomponents are
steatosis (0–3 points), inflammation (0–3 points), and
See Online for appendix
Research in context
Evidence before this study
Pemvidutide is a dual GLP-1 and glucagon receptor agonist being
evaluated for the treatment of metabolic dysfunction-associated
steatohepatitis (MASH). A PubMed search of results from clinical
trials published before Sept 24, 2025 with the search terms
(“GLP-1” OR “glucagon-like peptide”) AND (“glucagon”) AND
(“MASH” OR “NASH”) AND (“phase 2” OR “phase 3”) identified
five randomised clinical trials evaluating an incretin-based agent
in patients with biopsy-confirmed MASH, including one phase 3
trial. Each of these studies evaluated treatment regimens of
48 weeks or longer. The phase 2 trials included a 48-week trial of
the GLP-1–glucagon dual receptor agonist survodutide. Each of
the phase 2 studies showed MASH resolution or improvement
without worsening of fibrosis, although none of these trials
showed significant fibrosis improvement without worsening of
MASH by use of statistical standards by which patients with
missing data due to missing biopsies or treatment
discontinuations were treated as non-responders.
Added value of this study
Treatment with pemvidutide for 24 weeks led to a significant
proportion of patients achieving MASH resolution without
worsening of fibrosis at a shorter time interval than previous
phase 2 studies of incretin therapies. Further, this study is,
we believe, the first incretin-based study in MASH to show
significant clinical activity and good tolerability in the absence
of dose titration.
Implications of all the available evidence
The body of evidence highlights the utility of dual
GLP-1–glucagon receptor agonists for the treatment of MASH.
The efficacy and safety of pemvidutide in larger cohorts and
over longer time periods is yet to be established. The findings
here, and in other studies, support the continued investigation
of pemvidutide in patients with MASH.
Articles
3www.thelancet.com Published online November 11, 2025 https://doi.org/10.1016/S0140-6736(25)02114-2
hepatocyte ballooning (0–2 points). In addition, patients
were required to have confirmed F2 or F3 fibrosis
following non-alcoholic steatohepatitis (NASH) Clinical
Research Network (CRN) conventions.
14
Biopsies, taken
at the time of screening or within 6 months before
screening, if historical, served as the baseline for
histological measures. Notable other inclusion criteria
included BMI at least 27·0 kg/m
2
, magnetic resonance
imaging proton density fat fraction (MRI-PDFF) at least
8%, and liver stiffness measurement (LSM) at least
8·5 kPa. Key exclusion criteria included non-MASH
chronic liver disease, consuming more than 14 (females)
or more than 21 (males) alcohol units per week, and
medications that might induce steatosis or steatohepatitis.
A complete list of inclusion and exclusion criteria is
located in the appendix (pp 2–7).
Randomisation and masking
Patients were randomly assigned in a 1:2:2 ratio to receive
1·2 mg or 1·8 mg pemvidutide or placebo via once-
weekly subcutaneous injection for 48 weeks. Dose
titration was not used at either pemvidutide dose.
Patients, investigators, central reviewers, and other study
personnel were unaware of study group assignments.
Randomisation was done via an interactive web response
system following a list drawn up by an independent
statistician. Randomisation was stratified by fibrosis
stage at baseline (F2 or F3) and the presence or absence
of type 2 diabetes.
Procedures
A post-treatment liver biopsy was planned at week 24 to
measure primary efficacy (appendix p 10), with follow-up
for safety, weight loss, and non-invasive tests at 48 weeks.
Biopsies were scored independently by three pathologists
masked to patient, treatment, and sampling sequence
(appendix p 10).
Outcomes
The study had two dual primary endpoints established by
histological assessment of liver biopsy samples, both
measured at 24 weeks. The first dual endpoint was the
proportion of patients achieving MASH resolution,
defined as at least a 2-point reduction in NAS with no
hepatocyte ballooning and a score of 0 or 1 in the lobular
inflammation component of NAS, without worsening of
fibrosis stage. The second dual primary endpoint was
fibrosis improvement, defined as the proportion of
patients achieving at least a one-stage improvement in
liver fibrosis (per NASH CRN criteria) without worsening
of NAS score at 24 weeks.
Secondary endpoints at 24 weeks included the proportion
of patients achieving both MASH resolution and at least a
one-stage improvement in liver fibrosis, relative change
from baseline in liver fat content established by MRI-PDFF,
the proportion of patients achieving 30%, 40%, or 50%
reduction in liver fat content from baseline per MRI-PDFF,
and normalisation of liver fat content (≤5%) per
MRI-PDFF. Other secondary endpoints included the
absolute change from baseline in corrected T1 (cT1)
relaxation time, the proportion of patients with an 80 ms
decrease in cT1 relaxation time, the absolute change from
baseline in alanine amino transferase (ALT), the proportion
of patients with a 17 international units (IU)/L decrease in
ALT relative to baseline, the absolute changes from
baseline in the Enhanced Liver Fibrosis (ELF) score,
FibroScan-aspartate aminotransferase (FAST) score,
N-terminal type III collagen propeptide (Pro-C3), fibrosis
(FIB)-4 index, and the proportion of patients with a
0·5 decrease in ELF score.
In a post-hoc analysis, liver biopsies were also read for
the proportionate area of fibrosis by the Liver Explore
(PathAI, Boston, MA, USA) artificial intelligence
(AI)-based algorithm to quantify the magnitude of fibrosis
in each biopsy specimen.
15
A full list of endpoints is provided in the appendix (p 8).
Statistical analysis
Based on previous trials of pemvidutide in patients with
MASLD,
13
a sample size of 190 patients was estimated to
provide 90% power to show a significant difference in
MASH resolution at 24 weeks between the 1·8 mg
pemvidutide and placebo groups, and 80% power to
show a significant difference in fibrosis improvement
between the 1·8 mg pemvidutide and placebo groups at
24 weeks with a two-sided significance of 0·05. For the
Figure 1: Trial profile
One patient randomly assigned to receive placebo received 1·2 mg pemvidutide. †One patient did not complete
24 weeks of treatment but underwent biopsy.
1557 patients screened
212 randomly assigned and dosed
86 assigned to placebo
1 lost to follow-up
8 discontinued
intervention
2 adverse event
1 prohibited
medication
5 withdrawal by
patient
3 discontinued
intervention
1 discretion of
investigator
1 patient travel
resulting in
missed doses
1 withdrawal by
patient
41 assigned to 1·2 mg
pemvidutide
1 lost to follow-up
6 discontinued
intervention
1 adverse event
1 elective bypass
surgery
1 prohibited
medication
3 withdrawal by
patient
85 assigned to 1.8 mg
pemvidutide
77 completed 24-week
treatment
72 biopsy results
available
5 biopsy refused or
uninterpretable
38 completed 24-week
treatment
37 biopsy results
available
1 biopsy refused or
uninterpretable
78 completed 24-week
treatment
79 biopsy results
available†
Articles
www.thelancet.com Published online November 11, 2025 https://doi.org/10.1016/S0140-6736(25)02114-24
endpoint of MASH resolution, the power calculation
assumed a response rate of 45% in the 1·8 mg group and
20% in the placebo group. The fibrosis improvement
endpoint assumed 42% response in the 1·8 mg group
and 20% response in the placebo group.
Primary and secondary endpoints were analysed in the
intention-to-treat population comprised of all randomly
assigned patients, all of whom also received at least
one dose of pemvidutide or placebo. Statistical analysis
of the primary endpoints involved dual binary outcomes
indicating successful response to treatment
(MASH resolution or fibrosis improvement) employing
a sequential hierarchal testing procedure, with MASH
resolution preceding fibrosis improvement. The
Placebo
(n=86)
Pemvidutide 1·2 mg
(n=41)
Pemvidutide 1·8 mg
(n=85)
Total
(n=212)
Age, years52·5 (12·2)55·2 (13·0)53·4 (12·4)53·4 (12·4)
Self-reported sex
Female48 (56%)25 (61%)50 (59%)123 (58%)
Male38 (44%)16 (39%)35 (41%)89 (42%)
Race*
American Indian or Alaska Native002 (2%)2 (1%)
Asian1 (1%)1 (2%)3 (4%)5 (2%)
Black3 (3%)003 (1%)
Native Hawaiian or Pacific Islander1 (1%)01 (1%)2 (1%)
White78 (91%)37 (90%)76 (89%)191 (90%)
Unknown01 (2%)1 (1%)2 (1%)
Other3 (3%)2 (5%)2 (2%)7 (3%)
Ethnicity*
Hispanic or Latinx38 (44%)18 (44%)43 (51%)99 (47%)
Not Hispanic or Latinx48 (56%)23 (56%)41 (48%)112 (53%)
Not reported001 (1%)1 (<1%)
Bodyweight, kg109·7 (28·0)110·7 (26·3)107·7 (21·3)109·1 (25·1)
Waist circumference, cm118·8 (18·8)123·5 (16·9)119·1 (14·
3)119·8 (16·8)
BMI, kg/m
2
38·3 (8·4)39·2 (8·4)38·7 (6·9)38·7 (7·8)
Liver fat content, %19·6% (6·4)20·0% (7·1)19·0% (6·8)19·4% (6·7)
Alanine aminotransferase, IU/L56·6 (32·7)67·6 (54·6)67·6 (43·0)63·2 (42·0)
Aspartate aminotransferase, IU/L44·9 (20·8)50·8 (26·8)51·0 (29·4)48·5 (25·8)
Type 2 diabetes37 (43%)19 (46%)36 (42%)92 (43%)
Fasting glucose, mg/dL123·4 (38·5)121·6 (42·2)126·7 (44·9)124·4 (41·7)
Glycated haemoglobin, %6·4% (1·0)6·3% (1·1)6·5% (1·2)6
·4% (1·1)
Total cholesterol, mmol/L4·7 (1·2)5·0 (1·1)4·7 (1·1)4·7 (1·1)
High-density lipoprotein, mmol/L1·2 (0·4)1·1 (0·3)1·2 (0·3)1·2 (0·4)
Low-density lipoprotein, mmol/L2·6 (1·0)3·0 (1·1)2·6 (1·0)2·7 (1·0)
Triglycerides, mmol/L1·9 (1·0)1·9 (0·7)1·9 (1·0)1·9 (1·0)
Blood pressure, mm Hg
Systolic125·7 (13·0)125·3 (13·7)124·2 (13·4)125·0 (13·3)
Diastolic79·4 (7·3)76·1 (8·4)78·9 (7·8)78·5 (7·8)
Non-alcoholic fatty liver disease activity score†5·2 (0·9)5·1 (1·0)5·2 (1·0)5·2 (1·0)
Controlled attenuation parameter, dB/m342·5 (33·2)336·5 (35·1)342·9 (33·0)341·6 (33·3)
Enhanced Liver Fibrosis score9·7 (0·8)10·0 (0·8)9·9 (1·0)9·9 (0·9)
Liver stiffness, kPa12·5 (4·4)12·3 (3·6)12·8 (4·4)12·6 (4·
2)
Corrected T1 relaxation time, ms984·7 (132·7)976·1 (159·3)969·4 (123·5)977·0 (133·6)
Liver fibrosis stage
F246 (53%)24 (59%)46 (54%)116 (55%)
F340 (47%)17 (41%)39 (46%)96 (45%)
Data are presented as n (%) or mean (SD). Percentages might not total 100 owing to rounding. *Self-reported by patients. †The non-alcoholic fatty liver disease activity score
(scale of 0 to 8; high scores indicate more severe disease) characterised by the NASH Clinical Research Network incorporates scores for steatosis (0–3 points), lobular
inflammation (0–3 points), and hepatocellular ballooning. NASH=non-alcoholic steatohepatitis.
Table 1: Baseline characteristics
Articles
5www.thelancet.com Published online November 11, 2025 https://doi.org/10.1016/S0140-6736(25)02114-2
specified order of statistical testing was MASH
resolution at 1·8 mg, fibrosis improvement at 1·8 mg,
MASH resolution at 1·2 mg, and fibrosis improvement
at 1·2 mg. An intention-to-treat treatment policy
estimand was applied, as described in the statistical
analysis plan, with missing outcomes due either to
missing biopsies or treatment discontinuations treated
as non-responders (composite estimand). Logistic
regression analyses were used to calculate the difference
in proportions, with corresponding 95% CIs between
the pemvidutide groups and placebo. For the primary
efficacy analyses, p values were obtained by use of the
χ²-test at a two-sided significance level of 0·05. Secondary
endpoint analyses of continuous variables limited to
one or two pretreatment and post-treatment
measurements, including changes from baseline in liver
fat content, cT1 relaxation time, and fibrosis markers
were compared between pemvidutide and placebo by
use of statistical tests based on ANCOVA. Continuous
measures with multiple measurements, such as weekly
changes in bodyweight, waist circumference, serum
ALT, blood pressure, and heart rate, were analysed by
use of a mixed model for repeated measures. Point
estimates were presented as least-squares means. The
Cochran–Mantel–Haenszel test was applied to secondary
endpoints that were categorical in nature. Adverse
events were analysed in the safety population, comprised
of patients receiving at least one dose of pemvidutide or
placebo and reported with descriptive statistics. Patients
were analysed by the treatment to which they were
randomly assigned. Statistical analyses were done with
SAS version 9.4. The full statistical analysis plan is
presented in the appendix (p 118). The safety of patients
was monitored by an independent Data Monitoring
Committee.
Role of the funding source
The funder had a role in the study design, data collection,
data analysis, data interpretation, and writing of the
report.
Results
Between July 27, 2023, the date at which the first patient
was screened, and April 29, 2025, the date at which the last
patient completed 24 weeks of treatment, 1557 potential
patients were screened for eligibility, of which 212 patients
were randomly assigned to 1·2 mg pemvidutide
(41 patients), 1·8 mg pemvidutide (85 patients), or
placebo (86 patients; figure 1). Of those patients,
193 (91%) completed week 24 of the trial and 188 (89%)
had interpretable 24-week biopsy results. The reasons for
ineligibility on screening are presented in the appendix
(p 12). One patient randomly assigned to the placebo
group received 1·2 mg pemvidutide but was included in
the placebo group for the intention-to-treat analysis.
Demographic and clinical characteristics, which were
similar across groups, are presented in table 1 and the
appendix (p 13). 123 (58%) patients were female. The
NAS at baseline was 4 (31%) in 66 patients, 5 (33%) in
71 patients, 6 (25%) in 53 patients, and 7 (10%)
in 22 patients. Baseline biopsies revealed F2 fibrosis in
116 (55%) of 212 patients and F3 fibrosis in
96 (45%) patients.
In the intention-to-treat analysis employing the
composite estimand strategy, with missing outcomes
owing either to missing biopsies or treatment
discontinuations treated as non-responders, the primary
endpoint of MASH resolution without worsening of
fibrosis at week 24 was statistically higher with 1·2 mg
pemvidutide compared with placebo (24 [58%] of 41 vs
18 [20%] of 86; difference of 38% [95% CI 21 to 56];
p<0·0001) and with 1·8 mg pemvidutide versus placebo
(45 [52%] of 85 vs 18 [20%] of 86; difference of 32%
[95% CI 19 to 46]; p<0·0001; figure 2A). There was no
statistical difference in the proportion of patients who
had fibrosis improvement without worsening of MASH
at week 24 between the 1·2 mg pemvidutide group and
placebo (13 [33%] of 41 vs 24 [28%] of 86; difference of
5% [95% CI −13 to 22]; p=0·59) nor the 1·8 mg
pemvidutide group and placebo (30 [36%] of 85 vs 24
[28%] of 86; difference of 8% [95% CI −6 to 22]; p=0·27;
figure 2B). The secondary endpoint of the proportion of
patients with combined MASH resolution and ≥1 stage
fibrosis improvement was seen in ten (24%) of
41 patients in the 1·2 mg pemvidutide group, 21 (24%) of
85 patients in the 1·8 mg group, and 13 (14%) of
86 patients in the placebo group (appendix p 15). A
Figure 2: Primary endpoints
(A) The least-squares mean proportion of patients with resolution of MASH without worsening of fibrosis after
24 weeks of treatment; error bars represent SE; MASH resolution was defined as at least a 2-point reduction in NAS
(scale of 0 to 8, with higher scores indicating more severe disease), no hepatocyte ballooning, and a score of 0 or 1
in the lobular inflammation component of the score, without worsening fibrosis. (B) The least-squares mean
proportion of patients with liver fibrosis improvement without worsening of MASH after 24 weeks of treatment,
defined as the proportion of patients achieving at least a one-stage improvement in liver fibrosis without
worsening of NAS; error bars represent SE. A composite strategy was employed that considered patients with
missing outcomes due either to missing biopsies or treatment discontinuations as non-responders. Data were
analysed with the use of the chi-square test. MASH=metabolic dysfunction-associated steatohepatitis. NAS=non-
alcoholic fatty liver disease activity score.
Difference, 5% (95% CI –13 to 22)
p=0·59
Difference, 8% (95% CI –6 to 22)
p=0·27
24 (28%)
13 (33%)
30 (36%)
Difference, 38% (95% CI 21 to 56)
p<0·0001
Difference, 32% (95% CI 19 to 46)
p<0·0001
18 (20%)
24 (58%)
45 (52%)
placebo
n=86
1·2 mg
n=41
1·8 mg
n=85
0
10
20
30
40
50
60
70
80
90
100
AB
Least-squares mean proportion of patients (%)
Pemvidutide
placebo
n=86
1·2 mg
n=41
1·8 mg
n=85
Pemvidutide
Articles
www.thelancet.com Published online November 11, 2025 https://doi.org/10.1016/S0140-6736(25)02114-26
Placebo (n=86)Pemvidutide 1·2 mg (n=41)Pemvidutide 1·8 mg (n=85)
Non-alcoholic fatty liver disease activity score
Absolute change from baseline−1·3 (0·1)−2·9 (0·2)−2·6 (0·1)
Least-squares mean difference from placebo (95% CI)··−1·6 (−2·1 to −1·1)−1·4 (−1·8 to −1·0)
p value··<0·001<0·001
Liver fat reduction
Relative change
Value−11·4 (3·0)−52·0 (4·2)−57·7 (3·0)
Least-squares mean difference from placebo (95% CI)··−40·6 (−50·9 to −30·4)−46·3 (−54·6 to −38·0)
p value··<0·001<0·001
Decrease of ≥30%, percentage of patients15/76 (20%)32/39 (82%)66/79 (84%)
p value··<0·0001<0·0001
Decrease of ≥40%, percentage of patients12/76 (16%)29/39 (74%)63/79 (80%)
p value··<0·0001<0·0001
Decrease of ≥50%, percentage of patients8/76 (11%)24/39 (62%)57/79 (72%)
p value··<0·0001<0·0001
Liver fat content normalisation, percentage of patients3/76 (4%)12/39 (31%)35/79 (44%)
p value··<0·0001<0·0001
Corrected T1 relaxation time, ms
Absolute change−14·7 (11·9)−124·6 (16·1)−134·7 (11·9)
Least-squares mean difference from placebo (95% CI)··−109·9 (−142·0 to −77·8)−120·0 (−144·4 to −95·6)
p value··<0·001<0·001
Decrease of 80 ms from baseline, percentage of patients18/64 (28%)21/27 (78%)49/66 (74%)
p value··<0·0001<0·0001
Alanine aminotransferase, IU/L
Absolute change−10·3 (2·4)−34·6 (3·3)−34·4 (2·3)
Least-squares mean difference from placebo (95% CI)··−24·3 (−32·3 to −16·3)−24·1 (−30·6 to −17·6)
p value··<0·001<0·001
Decrease of ≥17 IU/L, percentage of patients17/74 (23%)22/39 (56%)52/78 (67%)
p value··0·0003<0·0001
Aspartate aminotransferase, IU/L
Absolute change−6·9 (1·8)−23·7 (2·5)−25·0 (1·8)
Least-squares mean difference from placebo (95% CI)··−16·8 (−22·9 to −10·7)−18·0 (−23·1 to −13·
0)
p value··<0·001<0·001
Enhanced Liver Fibrosis score
Absolute change 0·03 (0·1)−0·6 (0·1)−0·5 (0·1)
Least-squares mean difference from placebo (95% CI)··−0·6 (−0·8 to −0·4)−0·5 (−0·7 to −0·3)
p value··<0·001<0·001
Decrease of ≥0·5 points, percentage of patients14/74 (19%)18/39 (46%)39/76 (51%)
p value··0·0021<0·0001
FibroScan-aspartate aminotransferase score
Absolute change−0·08 (0·02)−0·38 (0·04)−0·36 (0·02)
Least-squares mean difference from placebo (95% CI)··−0·30 (−0·38 to −0·21)−0·27 (−0·34 to −0·21)
p value··<0·001<0·001
Bodyweight, kg
Percentage change−0·5% (0·3)−4·8% (0·5)−5·8% (0·3)
Least-squares mean difference from placebo (95% CI)··−4·3 (−5·4 to −3·2)−5·2 (−6·1 to −4·3)
p value··<0·001<0·001
Waist circumference, cm
Percentage change0·9% (1·1)−3·2% (1·5)−3·5% (1·1)
Least-squares mean difference from placebo (95% CI)··−4·1 (−7·7 to −0·4)−4·4 (−7·3 to −1·4)
p value··0·0290·003
(Table 2 continues on next page)
Articles
7www.thelancet.com Published online November 11, 2025 https://doi.org/10.1016/S0140-6736(25)02114-2
Placebo (n=86)Pemvidutide 1·2 mg (n=41)Pemvidutide 1·8 mg (n=85)
(Continued from previous page)
Glycated haemoglobin, %
Absolute change0·03% (0·1)−0·14% (0·1)0·03% (0·1)
Least-squares mean difference from placebo (95% CI)··−0·17 (−0·4 to 0·1)0·0 (−0·2 to 0·2)
p value··0·170·97
Liver stiffness measurement, kPa
Absolute change −0·7 (0·5)−3·7 (0·7)−2·2 (0·5)
Least-squares mean difference from placebo (95% CI)··−3·0 (−4·6 to −1·4)−1·5 (−2·8 to −0·3)
p value··<0·0010·02
Decrease of ≥25%, percentage of patients16/76 (21%)26/37 (70%)33/78 (42%)
p value··<0·00010·0049
<10 kPa at week 24, percentage of patients18/51 (35%)19/25 (76%)24/56 (43%)
p value··0·0010·31
N-terminal type III collagen propeptide, μg/L
Absolute change−2·4 (1·6)−15·3 (2·2)−14·7 (1·5)
Least-squares mean difference from placebo (95% CI)··−12·9 (−18·2 to −7·7)−12·3 (−16·7 to −8·0)
p value··<0·001<0·001
Fibrosis-4 (FIB-4) score
Absolute change−0·06 (0·05)−0·34 (0·06)−0·31 (0·04)
Least-squares mean difference from placebo (95% CI)··−0·28 (−0·43 to −0·13)−0·25 (−0·37 to −0·13)
p value··<0·001<0·001
Enhanced Liver Fibrosis score and liver stiffness measurement
0·5 reduction in Enhanced Liver Fibrosis score + 25% reduction in liver
stiffness measurement, percentage of patients
5/70 (7%)16/37 (43%)17/73 (23%)
p value··<0·00010·008
Total cholesterol, mmol/L
Percentage change−2·0% (1·8)−8·0% (2·5)−6·4% (1·8)
Least-squares mean difference from placebo (95% CI)··−6·0 (−12·1 to 0·1)−4·4 (−9·3 to 0·6)
p value··0·0550·08
High-density lipoprotein, mmol/L
Percentage change2·5% (1·7)−2·4% (2·4)1·0% (1·7)
Least-squares mean difference from placebo (95% CI)··−4·9 (−10·7 to 0·8)−1·5 (−6·2 to 3·1)
p value··0·0930
·52
Low-density lipoprotein, mmol/L
Percentage change−2·2% (3·3)−7·0% (4·7)−3·6% (3·4)
Least-squares mean difference from placebo (95% CI)··−4·8 (−16·2 to 6·6)−1·4 (−10·7 to 7·8)
p value··0·410·76
Triglycerides, mmol/L
Percentage change−0·7% (3·3)−10·8% (4·6)−12·9% (3·3)
Least-squares mean difference from placebo (95% CI)··−10·0 (−21·2 to 1·1)−12·2 (−21·3 to −3·2)
p value··0·0760·009
Blood pressure, mm Hg
Systolic
Absolute change
0·6 (1·2)−4·8 (1·7)−4·2 (1·2)
Least-squares mean difference from placebo (95% CI)··−5·3 (−9·4 to −1·3)−4·8 (−8·0 to −1·5)
p value··0·010·005
Diastolic
Absolute change
0·1 (0·7)−1·1 (1·1)−1·6 (0·7)
Least-squares mean difference from placebo (95% CI)··−1·2 (−3·7 to −1·3)−1·7 (−3·8 to 0·3)
p value··0·350·10
(Table 2 continues on next page)
Articles
www.thelancet.com Published online November 11, 2025 https://doi.org/10.1016/S0140-6736(25)02114-28
post-hoc AI-based pathology assessment of biopsy slides
identified consistent and substantial decreases in the
proportionate area of pathological fibrosis with
pemvidutide treatment, including a reduction of at least
50% in up to 30 (35% of 85) of the 1·8 mg group
(appendix p 16).
Placebo (n=86)Pemvidutide 1·2 mg (n=41)Pemvidutide 1·8 mg (n=85)
(Continued from previous page)
Heart rate, beats per min
Absolute change0·4 (0·9)−0·8 (1·3)1·0 (0·9)
Least-squares mean difference from placebo (95% CI)··−1·2 (−4·3 to 1·9)0·6 (−1·9 to 3·0)
p value··0·440·65
Data are presented as mean (SE) unless indicated otherwise. Comparisons versus placebo were made using mixed models for repeated measures for endpoints measured at
multiple timepoints and analysis of covariance for endpoints measured at baseline and week 24. The Cochran–Mantel–Haenszel test was applied to endpoints that were
categorical in nature. p values are nominal and calculated without adjustment for multiplicity.
Table 2: Change from baseline to week 24 in secondary efficacy endpoints
Figure 3: Secondary endpoints
(A) Absolute changes in alanine aminotransferase over the course of the trial. (B) Absolute changes in aspartate aminotransferase over the course of the trial. (C) The
relative change in weight from baseline at 24 weeks. (D) Relative changes in weight from baseline over the course of the trial. Change is shown as least-squares mean
change from baseline; error bars represent SE. Data were analysed with the use of the mixed model for repeated measures. p values are nominal and calculated
without adjustment for multiplicity.
024681012141618202224
–40
–35
–30
–25
–20
–15
–10
–5
0
5
Least-squares mean change from baseline (IU [SE])
Week
024681012141618202224
–40
–35
–30
–25
–20
–15
–10
–5
0
5
AB
Week
placebo n=861·2 mg n=41
Pemvidutide
1·8 mg n=85
–9
–8
–7
–6
–5
–4
–3
–2
–1
0
Least-squares mean change from baseline (%)
024681012141618202224
–7
–6
–5
–4
–3
–2
–1
0
1
CD
Week
Alanine aminotransferase Aspartate aminotransferase
(95% CI -5 to -3) p<0.001
(95% CI -6 to -4) p<0.001
–0·5
–4·8
–5·8
Articles
9www.thelancet.com Published online November 11, 2025 https://doi.org/10.1016/S0140-6736(25)02114-2
When considering liver fat content by volume as
established by MRI-PDFF, the 1·2 mg pemvidutide
group had a 52% relative reduction and the 1·8 mg
pemvidutide group had a 58% relative reduction in liver
fat from baseline, compared with an 11% relative
reduction in the placebo group (table 2). A relative
decrease in liver fat content of at least 30% was seen in
32 (82%) of 39 patients in the 1·2 mg pemvidutide group,
66 (84%) of 79 patients in the 1·8 mg pemvidutide group,
and 15 (20%) of 76 patients in the placebo group. Relative
reductions in liver fat of at least 50% were seen in
24 (62%) patients in the 1·2 mg pemvidutide group,
57 (72%) patients in the 1·8 mg pemvidutide group, and
eight (11%) patients in the placebo group. In the 1·2 mg
pemvidutide group, 12 (31%) patients had normalisation
of liver fat content to less than 5% at week 24, versus
35 (44%) in the 1·8 mg pemvidutide group, and three
(4%) in the placebo group.
Mean absolute changes in cT1 relaxation time were
−124·6 ms in the 1·2 mg pemvidutide group, −134·7 ms
in the 1·8 mg group, and −14·7 ms in the placebo group
(table 2). The number of patients achieving at least 80 ms
decrease in cT1 from baseline at 24 weeks was 21 (78%) of
27 in the 1·2 mg pemvidutide group, 49 (74%)
of 66 patients in the 1·8 mg group, and 18 (28%) of
64 patients in the placebo group.
The absolute changes in ALT at 24 weeks were
−34·6 IU/L in the 1·2 mg and −34·4 IU/L in the 1·8 mg
pemvidutide groups compared with −10·3 IU/L in the
placebo group (table 2). The numbers of patients with at
least 17 IU/L decrease in ALT were 22 (56%) of 39 patients
in the 1·2 mg pemvidutide group, 52 (67%) of 78 patients
in the 1·8 mg group, and 17 (23%) of 74 patients in the
placebo group. At 24 weeks, the mean absolute changes
in aspartate aminotransferase (AST) were −23·7 IU/L in
the 1·2 mg group, −25·0 IU/L in the 1·8 mg group, and
−6·9 IU/L in the placebo group (table 2). The time
courses of these changes are shown in figure 3A and B.
Pemvidutide was associated with a −0·6 change in
ELF score at 24 weeks in the 1·2 mg group and a
−0·5 change in the 1·8 mg group, compared with a
+0·03 change in the placebo group (table 2). In the
1·2 mg group, 18 (46%) of 39 patients had an ELF score
decrease of at least 0·5 points, compared with 39 (51%)
of 76 patients in the 1·8 mg group, and 14 (19%) of
74 patients in the placebo group. From baseline to
24 weeks, the mean decrease in FAST score was 0·38 in
the 1·2 mg group, 0·36 in the 1·8 mg group, and 0·08
in the placebo group (table 2). The mean change in
Pro-C3 was −15
·3 μg/L in the 1·2 mg group, −14·7 μg/L
in the 1·8 mg group, and −2·4 μg/L in the placebo
group (table 2; appendix p 17). FIB-4 scores decreased
from baseline to 24 weeks, with larger decreases in the
pemvidutide groups than placebo (table 2; appendix
p 18). The combination of a 0·5-point reduction in ELF
and a 25% reduction in LSM occurred in 16 (43%) of
37 patients in the 1·2 mg pemvidutide group,
17 (23%) of 73 patients in the 1·8 mg group, and five
(7%) of 70 patients in the placebo group (table 2).
The relative change in bodyweight at 24 weeks was
−4·8% in the 1·2 mg pemvidutide group, −5·8% in the
1·8 mg group, and −0·5% in the placebo group (table 2),
with weight loss appearing to continue at the end of
treatment (figure 3C, D). Waist circumference decreased
by 3·2% in the 1·2 mg group, 3·5% in the 1·8 mg group
and increased 0·9% in the placebo group (table 2).
Over 24 weeks, adverse events were reported in
32 (78%) of 41 patients receiving 1·2 mg pemvidutide,
69 (81%) of 85 patients receiving 1·8 mg pemvidutide,
and 58 (67%) of 86 patients receiving placebo (table 3).
Discontinuation from the trial due to adverse events
occurred in one (1%) patient in the pemvidutide groups
and two (2%) patients in the placebo group.
Gastrointestinal disorders were the most common
adverse events, with 98 (46%) of 212 reporting
Placebo
(n=86)
Pemvidutide
1·2 mg (n=41)
Pemvidutide
1·8 mg (n=85)
Any adverse event58 (67%)32 (78%)69 (81%)
Adverse event considered by the investigator to
be related to assigned treatment
21 (24%)19 (46%)50 (59%)
Any serious adverse event3 (3%)1 (2%) 3 (4%)
Serious adverse event considered by the
investigator to be related to assigned treatment
000
Adverse event leading to the discontinuation of
treatment
2 (2%)01 (1%)
Adverse event from any system organ class
Nausea12 (14%)9 (22%)35 (41%)
Mild8 (9%)8 (20%)28 (33%)
Moderate4 (5%)1 (2%)7 (8%)
Diarrhoea7 (8%)4 (10%)18 (21%)
Mild7 (8%)4 (10%)14 (16%)
Moderate004 (5%)
Constipation8 (9%)5 (12%)11 (13%)
Mild7 (8%)5 (12%)10 (12%)
Moderate1 (1%)01 (1%)
Hyperglycaemia adverse events7 (8%)2 (5%)12 (14%)
Mild6 (7%)1 (2%)6 (7%)
Moderate1 (1%)1 (2%)6 (7%)
Urinary tract infection2 (2%)3 (7%)14 (16%)
Mild2 (2%)1 (2%)10 (12%)
Moderate02 (5%)4 (5%)
Headache6 (7%)3 (7%)9 (11%)
Mild5 (6%)3 (7%)7 (8%)
Moderate1 (1%)02 (2%)
Nasopharyngitis2 (2%)5 (12%)3 (4%)
Mild2 (2%)4 (10%)1 (1%)
Moderate01 (2%)2 (2%)
Data are n (%). Shown are adverse events with an incidence of at least 10% in any trial group, according to the
preferred term in the Medical Dictionary for Regulatory Activities. No severe adverse events were reported for any
adverse events listed.
Table 3: Adverse events
Articles
www.thelancet.com Published online November 11, 2025 https://doi.org/10.1016/S0140-6736(25)02114-210
gastrointestinal events, including nausea, diarrhoea, and
constipation. No severe gastrointestinal events were
reported. Seven (3%) of 212 patients across the
pemvidutide and placebo groups reported serious
adverse events, and none were assessed as treatment
related. Details on serious adverse events are provided in
the appendix (p 14).
Changes in HbA
1c
at 24 weeks were −0·14, 0·03, and
0·03 in the 1·2 mg, 1·8 mg, and placebo groups,
respectively (table 2). Hyperglycaemic adverse events,
although higher in the 1·8 mg group, were generally
mild, episodic, did not require treatment, and did not
result in treatment discontinuation. Urinary tract
infections (UTIs) were reported in 19 (9%) of 212 total
patients across the three treatment groups. The urinary
tract infections were predominantly mild and
asymptomatic, with no severe events reported. There was
no association of urinary tract infection and
hyperglycaemia events; only two patients who had a
urinary tract infection also had a hyperglycaemia event.
The UTIs were considered unrelated to study drug in all
patients, and none of the events resulted in study drug
discontinuation. Systolic blood pressure decreased by
4·8 mm Hg in the 1·2 mg group and 4·2 mm Hg in the
1·8 mg group, versus a 0·6 mm Hg increase in the
placebo group, whereas diastolic blood pressure
decreased by 1·1 mm Hg and 1·6 mm Hg, and increased
by 0·1 mm Hg, respectively. The effects on heart rate
(−0·8, 1·0, and 0·4 beats per min in 1·2 mg, 1·8 mg, and
placebo, respectively), were similar across treatment
groups.
Discussion
This study marks the first incretin-based clinical trial in
MASH to report on histological outcomes after 24 weeks
of treatment. With respect to the dual primary efficacy
endpoints of the trial, pemvidutide met the MASH
resolution without worsening of the fibrosis endpoint at
24 weeks compared with placebo, but did not achieve a
significant difference from placebo in the second dual
primary endpoint of fibrosis improvement without
worsening of MASH at this timepoint.
The magnitude of MASH resolution at this early
24-week timepoint was similar to or greater than the
responses of other agents either approved or in
development for MASH, including agents with longer
treatment duration and at a shorter time interval than
previous phase 2 studies of other incretins.
8,16
Pemvidutide
was also associated with robust reductions and
normalisation in liver fat as measured by MRI-PDFF,
and reductions in the hepatic inflammation and injury
markers ALT, AST, and cT1 relaxation time. The reduction
in liver fat content was greater than that reported with
semaglutide treatment at 24 weeks,
8,17,18
reflective of the
recognised effects of glucagon on hepatic fat metabolism.
With regard to the secondary endpoints, significant
improvements in non-invasive markers of fibrosis
activity, including ELF, LSM, and Pro-C3, are potentially
indicative of an ongoing anti-fibrotic effect.
The post-hoc analyses of the proportionate area of
pathological liver fibrosis by use of Liver Explore
suggested significant improvement in fibrosis had
occurred but that resolution of the architectural features
that define F2 and F3 MASH, such as septal fibrosis, was
incomplete, and that a categorical one-stage improvement
in fibrosis might be achieved in a trial of longer duration.
Weight loss is central to the treatment of MASH as it
addresses the risks of obesity-related morbidity and
mortality. Obesity is a primary driver of MASH in most
people and although liver-related mortality increases with
fibrosis progression,
19
the most common cause of mortality
in patients with MASH is cardiovascular disease.
2
Thus,
treating both MASH and obesity might address multiple
major causes of morbidity and mortality in these patients.
The safety profile for pemvidutide shown here is
noteworthy, particularly as pemvidutide was administered
without dose titration, unique among trials of the incretin-
based class of agents. Despite having no dose titration
phase, the adverse event discontinuation rate for
pemvidutide was less than 1% and numerically lower than
placebo, a result unseen in other reported incretin-based
MASH studies.
8,10,16
Pemvidutide’s tolerability might be
related to the pharmacokinetics of pemvidutide, which is
marked by a prolonged
T
max
and reduced C
max
compared
with other peptide incretins.
20−22
The absence of dose
titration while maintaining good tolerability could be an
important advantage in the treatment of MASH patients
leading to improved retention of patients on therapy, as
adherence in the treatment of obesity with incretin-based
agents has been highlighted as a challenge.
23,24
Limitations of this trial include the moderate sample
size, which was typical of a phase 2 trial, and the reduced
cohort size for the 1·2 mg pemvidutide, which might
have complicated the establishment of a dose response.
Likewise, a 24-week readout could give an incom plete
interpretation of pemvidutide’s effect on hepatic fibrosis,
which might have been seen at a later timepoint typical
of other trials with GLP-1 based agents.
This phase 2 trial of once-weekly pemvidutide met the
primary endpoint of MASH resolution without worsening
of fibrosis at 24 weeks of treatment but did not meet the
second primary endpoint of fibrosis improvement.
Improvements were seen in multiple non-invasive tests
of fibrosis improvement and weight loss. Even at this
early timepoint, the magnitude of MASH resolution was
similar or greater than the responses of other agents
either approved or in development for MASH, including
agents with longer treatment duration.
8,16
The drug was
administered without dose titration and was associated
with a low rate of discontinuation due to drug-related
events, supporting its potential as a treatment for MASH
in patients with obesity. Larger and longer-duration trials
are needed to further evaluate its effects on fibrosis and
long-term outcomes.
Articles
11www.thelancet.com Published online November 11, 2025 https://doi.org/10.1016/S0140-6736(25)02114-2
Contributors
All authors had full access to all data in the study and final responsibility
for deciding to submit this manuscript for publication. MN and MSH
wrote the first draft of the manuscript with assistance from a medical
writer and with input from JJS, SK, and MSR. MN, JY and SK have
directly accessed and verified the data and statistical analyses
Declaration of interests
MN reports research support from Allergan, Altimmune, Akero,
BI, BMS, Boston Pharma, Conatus, Corcept, Gilead, Galectin, Genfit,
GSK, Kowa, Enanta, Madrigal, Eli Lilly, Merck, Novartis, Novo Nordisk,
Rivus, Shire, Takeda, Terns, Viking and Zydus; consulting fees from
Akero, Altimmune, Alligos, AstraZeneca, BI, Boston Pharma, Curve
Bioscience, Cytodyn, GSK, Histoindex, Kryia, Eli Lilly, Madrigal, Merck,
Novo Nordisk, OPKO, Rivus, Sagimet, Terns, and Takeda; speaking fees
from Madrigal and Novo Nordisk; has leadership roles at the journal
Clinical Gastroenterology and Hepatology (associate editor) and the
American Association for the Study of Liver Diseases (chair of the
metabolic dysfunction-associated steatotic liver disease special interest
group); and stock in Rivus Pharma, OPKO, Kryia, and Akero. RL reports
research support from Arrowhead Pharmaceuticals, AstraZeneca,
Boehringer Ingelheim, Bristol Myers Squibb, Eli Lilly, Galectin
Therapeutics, Gilead, Intercept, Hanmi, Inventiva, Ionis, Janssen,
John C Martin Foundation, Madrigal Pharmaceuticals, Merck,
US National Institutes of Health, Novo Nordisk, Pfizer, Sonic Incytes,
and Terns Pharmaceuticals; consulting fees from Aardvark Therapeutics,
Altimmune, Arrowhead Pharmaceuticals, AstraZeneca, Cascade
Pharmaceuticals, Eli Lilly, Gilead, Glympse Bio, Inipharma, Intercept,
Inventiva, Ionis, Janssen, Lipidio, Madrigal, Neurobo, Novo Nordisk,
Merck, Pfizer, Sagimet, 89 bio, Takeda, Terns Pharmaceuticals, and
Viking Therapeutics; is the co-founder of LipoNexus; and has stock in
Sagimet Biosciences. NA reports research support from 89bio, Akero
Therapeutics, Arbutus Biopharma, AstraZeneca, BioAge, Boehringer
Ingelheim, Bristol Myers Squibb, Corcept Therapeutics, Galectin
Therapeutics, Genentech, Gilead Sciences, Hepagene Therapeutics,
Intercept Pharmaceuticals, Inventiva Pharma, Ionis Pharmaceuticals,
Ipsen, Eli Lilly, Madrigal Pharmaceuticals, Merck, NGM
Biopharmaceuticals, NorthSea Therapeutics, Novo Nordisk, Perspectum,
Pfizer, PharmaIN, Poxel, Regeneron, Viking Therapeutics, and Zydus;
consulting fees from 89bio, AbbVie, Akero, Boehringer Ingelheim,
Echosens, Fibronostics, Gilead Sciences, HistoIndex, Intercept
Pharmaceuticals, Ipsen, LiverRight, Madrigal Pharmaceuticals,
NorthSea Therapeutics, Novo Nordisk, Perspectum, Pfizer, Regeneron,
and Sonic Incytes; and speaking fees from AbbVie, AstraZeneca,
Echosens, Gilead Sciences, Ipsen, Madrigal Pharmaceuticals, Novo
Nordisk, and Perspectum. NC reports research funding from Madrigal,
Exact Sciences, and Boehringer Ingelheim; consulting fees from
Madrigal, GSK, Altimmune, Chugai, Insitro, Zydus, Eccogene, Biomea,
and Ipsen; and stock in Heligenics and Avant Sante. MYS reports
research support from Akero Therapeutics, Altimmune, Allergan, 89bio,
Intercept Pharmaceuticals, Hanmi Pharmaceuticals, Salix
Pharmaceuticals, Madrigal Pharmaceuticals, Viking Therapeutics,
NGM Biopharmaceuticals, Eli Lilly, and Boston Pharmaceuticals; and
speaking fees from Madrigal Pharmaceuticals, Salix Pharmaceuticals,
and Gilead Sciences. ST is an employee of Altimmune; has a patent
pending with Altimmune; and holds stock and stock options in
Altimmune. JAG is an employee of Altimmune, has received consulting
fees from Altimmune; has received speaking fees from Gilead and
Madrigal; has participated in a data safety monitoring board or advisory
board with Surrozen and Escient; and holds stock in Altimmune. SU is
an employee of Altimmune. JJS is an employee of Altimmune; has
received travel support from Altimmune; has a patent pending with
Altimmune; and holds stock and stock options in Altimmune. RB is an
employee of Altimmune; has received travel support from Altimmune;
and holds stock and stock options in Altimmune. OO is an employee of
Altimmune. JY is an employee of Altimmune. SK is an employee of
Altimmune. GN reports consulting fees from Boehringer Ingelhelm,
Boston Pharmaceuticals, and Echosens. EM reports speaking fees from
Gilead, AbbVie, Madrigal Pharmaceuticals, and Ipsen; monitoring or
advisory board participation with Gilead, Madrigal, and Ipsen; and board
membership with HMRI non-profit and Salernis Collegium. MSR is an
employee of Altimmune; has received travel support from Altimmune;
and holds stock and stock options in Altimmune. SKB is an employee of
Altimmune; holds stock in and has received travel support from
Altimmune; has received speaking fees from Altimmune and is a lead
for the Altimmune scientific advisory board. MSH is an employee of
Altimmune; has received travel support from Altimmune; has a patent
pending with Altimmune; is an Altimmune company officer, and holds
stock and stock options in Altimmune. SAH is deceased and was unable
to provide a competing interest statement; to the best of our knowledge
he had no competing interests.
Data sharing
Aggregated data that supports the findings of this trial might be available
from the authors on reasonable request pending approval from
Altimmune. Individual participant-level data containing confidential or
identifiable participant information is covered by patient privacy and
cannot be shared.
Acknowledgments
This study was funded by Altimmune. Elizabeth W Brombosz and
Gražina Binkauskiene (Summit Clinical Research; paid by Altimmune)
assisted with writing and preparing the manuscript for submission.
References
1 Ho GJK, Tan FXN, Sasikumar NA, et al. High global prevalence of
steatotic liver disease and associated subtypes: a meta-analysis.
Clin Gastroenterol Hepatol 2025; published online May 5. https://doi.
org/10.1016/j.cgh.2025.02.006.
2 Younossi ZM, Kalligeros M, Henry L. Epidemiology of metabolic
dysfunction-associated steatotic liver disease. Clin Mol Hepatol 2025;
31 (suppl): S32–50.
3 Polyzos SA, Kountouras J, Mantzoros CS. Obesity and nonalcoholic
fatty liver disease: From pathophysiology to therapeutics.
Metabolism 2019; 92: 82–97.
4 Diehl AM, Day C. Cause, pathogenesis, and treatment of
nonalcoholic steatohepatitis. N Engl J Med 2017; 377: 2063–72.
5 Singh S, Allen AM, Wang Z, Prokop LJ, Murad MH, Loomba R.
Fibrosis progression in nonalcoholic fatty liver vs nonalcoholic
steatohepatitis: a systematic review and meta-analysis of paired-
biopsy studies. Clin Gastroenterol Hepatol 2015; 13: 643–54.
6 Younossi ZM, Golabi P, Price JK, et al. The global epidemiology of
nonalcoholic fatty liver disease and nonalcoholic steatohepatitis
among patients with type 2 diabetes. Clin Gastroenterol Hepatol
2024; 22: 1999–2010.e8.
7 Harrison SA, Bedossa P, Guy CD, et al, and the MAESTRO-NASH
Investigators. A phase 3, randomized, controlled trial of resmetirom
in NASH with liver fibrosis. N Engl J Med 2024; 390: 497–509.
8 Sanyal AJ, Newsome PN, Kliers I, et al, and the ESSENCE Study
Group. Phase 3 trial of semaglutide in metabolic dysfunction-
associated steatohepatitis. N Engl J Med 2025; 392: 2089–99.
9 Alkhouri N, Charlton M, Gray M, Noureddin M. The pleiotropic
effects of glucagon-like peptide-1 receptor agonists in patients with
metabolic dysfunction-associated steatohepatitis: a review for
gastroenterologists. Expert Opin Investig Drugs 2025; 34: 169–95.
10 Sanyal AJ, Bedossa P, Fraessdorf M, et al, and the 1404-0043 Trial
Investigators. A phase 2 randomized trial of survodutide in MASH
and fibrosis. N Engl J Med 2024; 391: 311–19.
11 Nestor JJ, Zhang X, Jaw-Tsai S, Parkes DG, Becker CK. Design and
characterization of a surfactant-conjugated, long-acting, balanced
GLP-1/glucagon receptor dual agonist. Pept Sci (Hoboken) 2021;
113: e24221.
12 Nauck MA, Niedereichholz U, Ettler R, et al. Glucagon-like peptide
1 inhibition of gastric emptying outweighs its insulinotropic effects
in healthy humans. Am J Physiol 1997; 273: E981–88.
13 Browne SK, Suschak JJ, Tomah S, et al. Safety and efficacy of
24 weeks of pemvidutide in metabolic dysfunction-associated
steatotic liver disease: a randomized, controlled clinical trial.
JHEP Rep Innov Hepatol 2025; 7: 101483.
14 Kleiner DE, Brunt EM, Van Natta M, et al, and the Nonalcoholic
Steatohepatitis Clinical Research Network. Design and validation of
a histological scoring system for nonalcoholic fatty liver disease.
Hepatology 2005; 41: 1313–21.
15 Pulaski H, Harrison SA, Mehta SS, et al. Clinical validation of an
AI-based pathology tool for scoring of metabolic dysfunction-
associated steatohepatitis. Nat Med 2025; 31: 315–22.
Articles
www.thelancet.com Published online November 11, 2025 https://doi.org/10.1016/S0140-6736(25)02114-212
16 Loomba R, Hartman ML, Lawitz EJ, et al, and the SYNERGY-
NASH Investigators. Tirzepatide for metabolic dysfunction-
associated steatohepatitis with liver fibrosis. N Engl J Med 2024;
391: 299–310.
17 Loomba R, Abdelmalek MF, Armstrong MJ, et al, and the
NN9931-4492 investigators. Semaglutide 2·4 mg once weekly in
patients with non-alcoholic steatohepatitis-related cirrhosis:
a randomised, placebo-controlled phase 2 trial.
Lancet Gastroenterol Hepatol 2023; 8: 511–22.
18 Flint A, Andersen G, Hockings P, et al. Randomised clinical trial:
semaglutide versus placebo reduced liver steatosis but not liver
stiffness in subjects with non-alcoholic fatty liver disease assessed
by magnetic resonance imaging. Aliment Pharmacol Ther 2021;
54: 1150–61.
19 Ekstedt M, Hagström H, Nasr P, et al. Fibrosis stage is the strongest
predictor for disease-specific mortality in NAFLD after up to
33 years of follow-up. Hepatology 2015; 61: 1547–54.
20 Aroda VR. A review of GLP-1 receptor agonists: Evolution and
advancement, through the lens of randomised controlled trials.
Diabetes Obes Metab 2018; 20 (suppl 1): 22–33.
21 Shi A, Xie P, Nielsen LL, Skjøth TV, He X, Haugaard SP.
Pharmacokinetics, safety and tolerability of once-weekly
subcutaneous semaglutide in healthy Chinese Subjects: a double-
blind, phase 1, randomized controlled trial. Adv Ther 2021; 38: 550–61.
22 Lawitz EJ, Fraessdorf M, Neff GW, et al, and the NCT05296733
Investigators. Efficacy, tolerability and pharmacokinetics of
survodutide, a glucagon/glucagon-like peptide-1 receptor dual
agonist, in cirrhosis. J Hepatol 2024; 81: 837–46.
23 Rodriguez PJ, Zhang V, Gratzl S, et al. Discontinuation and
reinitiation of dual-labeled glp-1 receptor agonists among US Adults
with overweight or obesity. JAMA Netw Open 2025; 8: e2457349.
24 Ladebo L, Ernst MT, Mailhac A, Dirksen C, Bojsen-Møller KN,
Pottegård A. Real-world use of semaglutide for weight
management: patient characteristics and dose titration—A Danish
cohort study. Diabetes Care 2024; 47: 1834–37.